scholarly journals Cognitive Impairment in Patients with Diabetes Mellitus

2019 ◽  
Author(s):  
Matveeva Mariia V. ◽  
Samoilova Yulia G. ◽  
Zhukova Natali G. ◽  
Rotkank Mariya A. ◽  
Tolmachev Ivan V. ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Cognitive Impairment ◽  
Patients With Diabetes

Cerebral microbleeds, cognitive impairment, and MRI in patients with diabetes mellitus

2017 ◽  
Vol 470 ◽  
pp. 14-19 ◽  
Author(s):  
Hong Zhou ◽  
Juan Yang ◽  
Peihan Xie ◽  
Yulan Dong ◽  
Yong You ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Cognitive Impairment ◽  
Cerebral Microbleeds ◽  
Patients With Diabetes

scholarly journals Characteristics of cognitive function in patients with diabetes mellitus type 1 younger depending transferred hypoglycemic conditions

2017 ◽  
pp. 17-21
Author(s):  
N. Zherdоva ◽  
B. Mankovsky
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Cognitive Impairment ◽  
Cognitive Function ◽  
Type 1 Diabetes Mellitus ◽  
Depression Scale ◽  
Diabetes Mellitus Type 1 ◽  
Diabetes Mellitus Type ◽  
Patients With Diabetes

Many studies focus on the effect of compensation of diabetes, glucose-lowering therapy of choice, the influence of cardio - vascular diseases in the state of cognition. At the same time, not enough attention is paid to cognitive impairment in patients with type 1 diabetes mellitus, especially young people. The aim of our study was to investigate the prognostic factors of dementia in patients with type 1 diabetes mellitus are younger. 33 patients were examined with type 1 diabetes and 10 people in the control group. Of the 33 patients with diabetes, 21 people had hypoglycemia in the last 3 months and 12 without hypoglycemic states. To identify depression used two questionnaires: Centre for Epidemiologic Studies Depression Scale (CES-D) and the Hospital Anxiety and Depression Scale (HAD). Evaluation of cognitive impairment was conducted using the following methods: The test "5 words", sample Schulte, the scale of assessment of mental status ( MMSE), test battery on the frontal dysfunction (BLD), evaluation of test o’clock. To reveal the 10-year risk of dementia patients used the scale which was developed by a team of researchers at Utrecht University Medical Rudolf Magnus. In patients with type 1 diabetes with hypoglycemia marked deterioration in cognitive function, according to the neuropsychological tests, namely the BLD and MMSE compared with  patient without hypoglycemia. The risk of developing dementia over 10 years in patients with diabetes mellitus type 1 young up 2.2 times compared with patients without hypoglycemia. Hypoglycemic state is the main risk factor that leads to the development of cognitive impairment, and this is a factor which can be influenced by insulin properly selected.

scholarly journals The relationship between cognitive impairment and decreased cerebral blood flow in the frontal area

2016 ◽  
pp. 26-29
Author(s):  
N. Zherdоva ◽  
B. Mankovsky
Keyword(s):  
Diabetes Mellitus ◽  
Blood Flow ◽  
Cerebral Blood Flow ◽  
Cognitive Impairment ◽  
Single Photon ◽  
Photon Emission ◽  
Cognitive Disorders ◽  
Stroop Test ◽  
Emission Computed Tomography ◽  
Patients With Diabetes

Diabetes mellitus is associated with increased risk of dementia, especially in patients with mild cognitive impairment, including changes which are unlikely to be found in everyday clinical practice, especially in patients with diabetes, which is associated with the presence of disease complications. Therefore, you must understand the importance of screening for cognitive disorders in the early stages in patients with diabetes mellitus. The aim of our study was to investigate the feasibility of the Stroop test to determine the state of cognitive impairment and cerebral blood flow status in the relevant areas of the brain evidenced by single-photon emission computed tomography (SPECT). The study involved 40 patients aged 60 to 70 years. The 27 women and 13 men. Exclusion criteria were the presence of stroke, traumatic brain injury, the abuse of alcohol. Evaluation of cognitive impairment was carried out using the Stroop test. For information on the perfusion of brain tissue using single photon emission computed tomography (SPECT). Patients were divided into 2 groups. The first group included patients who by SPECT were found hypofrontality, the second - with no signs of it. There has been a significant decrease in executive functions during the Stroop test of the part 3 in the patients of the first group than the second group. That is, the first group of patients, there is a decrease in cerebral blood flow in the anterior cingulate cortex and dorsolateral prefrontal cortex, which is confirmed by a SPECT of hypofrontality. Stroop test, a sensitive test in patients with diabetes mellitus type 2 and can be recommended for the diagnosis of cognitive disorders and diabetes associated disorders, for early detection of abnormalities in the cognitive field that will allow for the timely prevention of the condition and reduce the disability of patients.

scholarly journals Experience of actovegin use in a patient with cognitive impairment in diabetes mellitus (clinical case)

2020 ◽  
Vol 10 (1) ◽  
pp. 93-98
Author(s):  
M. V. Ovsyuk
Keyword(s):  
Diabetes Mellitus ◽  
Cognitive Impairment ◽  
Clinical Case ◽  
Glucose Utilization ◽  
Mechanisms Of Action ◽  
Late Complications ◽  
Diabetic Encephalopathy ◽  
Chronic Hyperglycemia ◽  
Number Of Patients ◽  
Patients With Diabetes

Diabetic encephalopathy is one of the late complications of diabetes mellitus arising from chronic hyperglycemia and cerebral macro- and microangiopathy. Cognitive impairment developing during diabetic encephalopathy and the associated maladaptation of patients become even more socially significant due to the rapid increase in the number of patients suffering from diabetes mellitus. In this regard, studies of drugs that improve cognitive functions in patients with diabetes mellitus are of the particular importance. Clinical case of a patient with cognitive impairment and diabetes mellitus treated with actovegin describes its effect on glucose utilization, as well as antioxidant, antihypoxant and other mechanisms of action that allow the drug to be used in patients with cognitive impairment CI on the background of diabetes mellitus.

FACTORS ASSOCIATED WITH COGNITIVE IMPAIRMENT IN ELDERLY PATIENTS WITH DIABETES MELLITUS

2006 ◽  
Vol 54 (3) ◽  
pp. 558-559 ◽  
Author(s):  
Mari Suzuki ◽  
Hiroyuki Umegaki ◽  
Satsuki Ieda ◽  
Nanaka Mogi ◽  
Akihisa Iguchi
Keyword(s):  
Diabetes Mellitus ◽  
Cognitive Impairment ◽  
Elderly Patients ◽  
Factors Associated ◽  
Patients With Diabetes

Dementia as a global problem of XXI century

2018 ◽  
Author(s):  
D. T. Abdukadirova ◽  
D. Y. Maksudova
Keyword(s):  
Diabetes Mellitus ◽  
Cognitive Impairment ◽  
Elderly Patients ◽  
Treatment Option ◽  
Social Problem ◽  
Cognitive Status ◽  
Treatment Approaches ◽  
Global Problem ◽  
Patients With Diabetes

Cognitive impairment in elderly patients with diabetes mellitus is an important medical and social problem. The article covers aspects of pathogenesis and treatment approaches of cognitive impairment and diabetes mellitus; in particular Tanacan as a treatment option for correction of cognitive status in patients with diabetes mellitus.

scholarly journals Cognitive impairment in patients with diabetes mellitus in the conditions of COVID-19

2021 ◽  
Vol 17 (5) ◽  
pp. 71-75
Author(s):  
N.M. Zherdova
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Cognitive Impairment ◽  
Cognitive Dysfunction ◽  
Cognitive Functions ◽  
Cognitive Disorders ◽  
Underlying Disease ◽  
The State ◽  
Patients With Diabetes

This review highlights the state of cognitive functions in patients with metabolic syndrome, diabetes mellitus at the stage of detection of the underlying disease and after COVID-19. The main links in the pathogenesis of cognitive dysfunction in patients with diabetes are explained, and based on previous studies of SARS-CoV-1 and MERS-CoV, possible mechanisms of cognitive impairment in patients infected with COVID-19 are revealed. Methods for the correction of cognitive disorders with the use of modern nootropics, such as phenibut, are proposed.

Sign in / Sign up

Export Citation Format

Share Document